Drugs / Cevostamab
Cevostamab
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07629583 | Jul 2026 → Mar 2030 expected | systemic lupus erythematosus | Genentech, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06934044 | May 2025 → Nov 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT05927571 | Aug 2023 → Jul 2027 expected | refractory plasma cell neoplasm | Genentech, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05646836 | Mar 2023 → Nov 2026 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04910568 | Jul 2021 → Dec 2028 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03275103 | Sep 2017 → Jan 2026 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05583617 | Nov 2023 → Jul 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05535244 | Oct 2022 → Feb 2027 expected | plasma cell myeloma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05801939 | Jul 2023 → May 2027 expected | refractory plasma cell neoplasm | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07555938 | Jun 2026 → Oct 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cevostamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07555938 ↗ |
| Known as | BFCR-4350A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297908 ↗ |
| Known as | RO-7187797 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297908 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4297908 ↗ |
| Route | Intravenous | “administered intravenously” NCT03275103 ↗ |